drugset
drugset / Trial / NCT06878170

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

NCT06878170 ↗

Phase 1 Active not recruiting 60 enrolled Rock BioMedical, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

Timeline

Start
2024-09-30
Primary completion
2025-05-30
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator RBM-001 Vaccine — Intramuscular

Indications

COVID-19